16:51 , Apr 22, 2019 |  BioCentury  |  Finance

Poseida's sea change

Rather than execute the IPO it proposed in January, Poseida has instead raised a $142 million series C round that includes a $75 million contribution from Novartis. CEO Eric Ostertag told BioCentury that Poseida has...
21:28 , Apr 18, 2019 |  BC Extra  |  Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

Arrakis raised $75 million in a series B round led by venBio and Nextech Invest. Also participating were new investors Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and Alexandria Venture...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
10:00 , Apr 18, 2019 |  BC Extra  |  Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
21:58 , Apr 17, 2019 |  BC Extra  |  Preclinical News

Salk study unveils LIF's mechanism in form of pancreatic cancer

A new study from Salk Institute for Biological Studies pinpoints new mechanistic details about how LIF promotes pancreatic cancer, providing preclinical support for Northern Biologics' lead candidate. In a Nature paper published Wednesday, Salk's Tony...
18:52 , Apr 17, 2019 |  BC Extra  |  Politics & Policy

Cummings defends drug price information request

House Energy & Commerce Committee Chairman Elijah Cummings (D-Md.) Wednesday denounced Jim Jordan (R-Ohio) for attempting to thwart the committee’s investigation into prescription drug prices. Cummings was responding to a letter Jordan sent on April...
18:46 , Apr 12, 2019 |  BC Week In Review  |  Company News

Sorrento sues NantWorks' Soon-Shiong over alleged 'catch and kill' scheme

Sorrento filed two lawsuits against Patrick Soon-Shiong and companies under his NantWorks umbrella for allegedly buying cancer therapy Cynviloq, a potential competitor to Abraxane nab-paclitaxel, through a "catch and kill" scheme to prevent it from...
16:40 , Apr 12, 2019 |  BC Extra  |  Company News

BMS, Celgene shareholders approve acquisition

Shareholders from both BMS and Celgene voted Friday to approve the pharma's acquisition of the biotech for $74 billion in a cash and stock deal. While the deal had its share of opposition and support,...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...